Eurazeo (RF) - Total Liabilities

Latest as of December 2025: €1.70 Billion EUR ≈ $1.98 Billion USD

Based on the latest financial reports, Eurazeo (RF) has total liabilities worth €1.70 Billion EUR (≈ $1.98 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Eurazeo growing its equity to track the company's year-over-year net asset growth rate.

Eurazeo - Total Liabilities Trend (2003–2025)

This chart illustrates how Eurazeo's total liabilities have evolved over time, based on quarterly financial data. See Eurazeo (RF) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Eurazeo Competitors by Total Liabilities

The table below lists competitors of Eurazeo ranked by their total liabilities.

Company Country Total Liabilities
Zhejiang Orient Holdings Co Ltd
SHG:600120
China CN¥44.10 Billion
BSP Financial Group Ltd
AU:BFL
Australia AU$37.82 Billion
AUB Group Ltd
AU:AUB
Australia AU$2.77 Billion
Uxi Unicomp Technology Co. Ltd. A
SHG:688531
China CN¥516.58 Million
Disc Medicine Inc.
NASDAQ:IRON
USA $61.78 Million
Bausch Health Companies Inc
TO:BHC
Canada CA$25.58 Billion
Co-Tech Development
TWO:8358
Taiwan NT$1.91 Billion

Liability Composition Analysis (2003–2025)

This chart breaks down Eurazeo's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Eurazeo market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.36 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.27 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.21 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Eurazeo's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Eurazeo (2003–2025)

The table below shows the annual total liabilities of Eurazeo from 2003 to 2025.

Year Total Liabilities Change
2025-12-31 €1.70 Billion
≈ $1.98 Billion
-9.32%
2024-12-31 €1.87 Billion
≈ $2.19 Billion
+32.47%
2023-12-31 €1.41 Billion
≈ $1.65 Billion
-85.25%
2022-12-31 €9.57 Billion
≈ $11.19 Billion
+20.69%
2021-12-31 €7.93 Billion
≈ $9.27 Billion
+2.65%
2020-12-31 €7.73 Billion
≈ $9.04 Billion
+6.07%
2019-12-31 €7.29 Billion
≈ $8.52 Billion
+24.68%
2018-12-31 €5.84 Billion
≈ $6.83 Billion
+4.92%
2017-12-31 €5.57 Billion
≈ $6.51 Billion
+8.27%
2016-12-31 €5.14 Billion
≈ $6.01 Billion
+95.79%
2015-12-31 €2.63 Billion
≈ $3.07 Billion
-70.10%
2014-12-31 €8.79 Billion
≈ $10.27 Billion
-0.46%
2013-12-31 €8.83 Billion
≈ $10.32 Billion
-13.50%
2012-12-31 €10.21 Billion
≈ $11.93 Billion
-4.44%
2011-12-31 €10.68 Billion
≈ $12.49 Billion
+4.41%
2010-12-31 €10.23 Billion
≈ $11.96 Billion
-5.20%
2009-12-31 €10.79 Billion
≈ $12.62 Billion
-3.47%
2008-12-31 €11.18 Billion
≈ $13.07 Billion
+3.07%
2007-12-31 €10.85 Billion
≈ $12.68 Billion
+2204.45%
2003-12-31 €470.68 Million
≈ $550.27 Million
--

About Eurazeo

PA:RF France Asset Management
Market Cap
$3.70 Billion
€3.17 Billion EUR
Market Cap Rank
#5269 Global
#90 in France
Share Price
€49.60
Change (1 day)
+4.64%
52-Week Range
€37.78 - €61.05
All Time High
€84.15
About

Eurazeo SE is a private equity and venture capital firm specializing in growth capital, series C, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in upper mid-market, mid-market and listed public companies, small- and mid-cap healthcare companies, equity in the small-mid and mid-large buyout segments. The firm seeks to invest in medium-sized or large companies, … Read more